Cerba Research

Genomics Services at Cerba Research

Use next-generation sequencing (NGS) to improve patient outcomes and inform clinical decision-making in oncology, rare diseases, infectious diseases, virology and more.

Cerba Research is committed to supporting you with the most insightful and state-of-the-art genomics technology platforms. At Cerba Research we have optimized our genomics workflow and support through scientific expertise to unleash the full potential of your therapeutic agent and advance your clinical trial.

Customized and off-the-shelf NGS assays

Enhanced quality control and data management

Comprehensive data analysis and interpretation

Additional genomics services include

qPCR	Genotyping (mass array)	miRNA analysis
ddPCR	Optical genome mapping	CGH array
PGx	Cytogenetic/FISH	HLA Typing

Our NGS Workflow

Cerba Research

Sample Preparation & extraction	Cerba Research offers fully automated genomic extraction platforms capable of extracting genomic material from various sample types, including FFPE tissue, flash frozen biopsies, whole blood, PBMCs, plasma, serum, and more !
Library Preparation	Customers can choose from multiple library preparation methods for solid tumors, hematological malignancies, rare disorders, hereditary disorders, infectious diseases, neurological disorders, and more to meet their unique NGS needs to support their clinical trial.
Sequencing	Sequencing at Cerba Research enables highly accurate and comprehensive sequencing of DNA, RNA, and other genetic material on an Illumina platform, providing unprecedented insights into genomic alterations of your various diseases.
Bioinformatics & Data Interpretation	Cerba Research's robust bioinformatics pipelines and expert data interpretation provide comprehensive and accurate analyses of complex genomic data, enabling valuable insights into resistance mechanisms and potential therapeutic targets.
Results & Data Storage	Cerba Research's customized NGS data reports and secure data storage options ensure efficient data management and tailored, actionable insights for each client's unique research needs.

Discover our Oncosign FFPE & ctDNA For Solid Tumors

Cerba Research OncoSign FFPE & ctDNA panels, alongside our OncoSign600+, covers mutations with established, emerging and exploratory value across lung, ovarian, breast, colon, melanoma, bladder, GIST, rare tumors and more. It can also determine MSI-H, TMB, HRD status and will be on FFPE & ctDNA (liquid biopsies).

DNA

AKT1, ALK, AR, BRCA1, BRCA2, BAP1, BRAF, CDK4, CDK6, CTNNB1, EGFR, ERBB2, ESR1, EIF1AX, FGFR2, FGFR3, FOXL2, GNA11, GNAQ, GNAS, ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, MAP2K1, MET, MYD88, NRAS, FGFR3, KRAS, MET, NRG1, NTRK1, NTRK2, RAF1, RET, SF3B1, STK11, NTRK3, PIK3CA, PPARG, ROS1, RET, and more...*

Microsatellites

BAT25, BAT26, D2S123, D5S346, D17S250, NR-21, NR-24, MONO-27, ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, SULF2

RNA – Fusion

ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, PIK3CA, PPARG, ROS1, RET

The gene list and samples requirement if for OncoSign FFPE only.
*The gene list is not exhaustive - please contact us for further information.